Al-Obaidi Ammar, Parker Nathaniel A, Hussein Agha Yasmine, Alqam Hamzah, Page Seth
Internal Medicine, University of Kansas School of Medicine, Wichita, USA.
Internal Medicine, Ascension Via Christi St. Francis, Wichita, USA.
Cureus. 2020 Jun 5;12(6):e8462. doi: 10.7759/cureus.8462.
Myeloid sarcoma is an isolated extramedullary tumor mass consisting of immature myeloid cells. It is characterized by highly variable outcomes and usually disrupts the normal architecture of the normal tissue in which it originates. It may occur de novo or be associated with other hematological malignancies. Clinical presentation of myeloid sarcomas can be highly variable based on the tumor site, size, and extent of tissue involvement. The diagnosis of myeloid sarcoma is challenging and requires a high index of suspicion. Tissue sampling followed by the use of auxiliary studies is essential for diagnosis. Moreover, bone marrow sampling is necessary to exclude morrow involvement. Currently, the recommended therapeutic regimens for myeloid sarcoma are similar to those for acute myeloid leukemia. Much work remains to be accomplished as myeloid sarcomas, if initially missed or misdiagnosed, have poor overall survival rates. Furthermore, prognostic factors for this malignancy remain poorly understood.
髓系肉瘤是一种由未成熟髓系细胞组成的孤立性髓外肿瘤块。其特点是预后差异很大，通常会破坏其起源正常组织的正常结构。它可原发发生，也可与其他血液系统恶性肿瘤相关。髓系肉瘤的临床表现因肿瘤部位、大小和组织受累程度而异。髓系肉瘤的诊断具有挑战性，需要高度怀疑。组织取样并随后进行辅助检查对诊断至关重要。此外，骨髓取样对于排除骨髓受累是必要的。目前，髓系肉瘤的推荐治疗方案与急性髓系白血病相似。由于髓系肉瘤如果最初漏诊或误诊，总体生存率较差，因此仍有许多工作要做。此外，这种恶性肿瘤的预后因素仍知之甚少。
